This report is the fifth edition of our analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.
Scope
This 53-page report gives important, expert insight you won’t find in any other source. 12 tables and 19 figures throughout the report illustrate major points and trends. This report is required reading for :- CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
- Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity and stock analysts: target identification and analysis, portfolio company performance benchmarking
Reasons to Buy
- Overview of M&A in the Pharma CMO Industry
- Detailed view of CDMO performance by number of deals, based on the analyst's Deals database
- Analysis of M&A and private equity investment by target's specific manufacturing services
Table of Contents
- Executive Summary
- Players
- Technology Briefing
- Deal types.
- Trends
- Industry Analysis
- Objectives and methodology
- Overview of M&A activity 2023
- Target characteristics
- Acquirer characteristics
- Geography
- Top acquirers
- Biosynth acquires Celares and Pepceuticals
- IPCA Laboratories invests in Unichem
- Target segment close-ups
- Multi
- API-small molecule
- API-biologic
- Commercial dose manufacturing
- Deal advisors.
- Top financial advisors
- Top legal advisors
- Valuations
- Facility acquisitions
- What it means
- Drug shortages drive low-tech small molecule deals.
- Multi-service and injectable manufacturers targeted
- Catalent acquisition shakes up pharma and CMO landscape.
- Biologic acquisitions decreased in 2023 but strong interest remains, despite BIOSECURE Act complicating manufacturing agreements
- Private equity investments declined
- The outlook for M&A
- API - biologic targets
- API - cell and gene therapy targets
- Value Chain
- Companies
- Appendix
- Methodology
- Bibliography
- Primary research - key opinion leaders
- Further reading
- About the Authors
Table 1: CMO M&A trends, 2023
Table 2: Company acquisitions by target service offering and year, 2018-23
Table 3: Company acquisitions by target service offering and target ownership, 2023
Table 4: Company acquisitions by target service offering and deal region, 2023
Table 5: Company acquisitions by target service offering and acquirer ownership, 2023
Table 6: Services deals with known transaction value and multiples, 2023
Table 7: Facility acquisitions by CMOs, 2023
Table 8: Private equity deals, 2023
Table 9: Potential targets: API - biologic (protein & peptide) service providers
Table 10: Potential targets: API - biologic (gene and cell therapy) service providers
Table 11: Company acquisitions and private equity deals, 2023
Table 12: Further reading
List of Figures
Figure 1: Leading acquirers in the global pharma CMO industry, 2023
Figure 2: Top M&A trends, 2023
Figure 3: CMO M&A activity, 2023
Figure 4: CMO M&A activity by year, 2018-23
Figure 5: CMO M&A activity percentage change by year, 2019-23
Figure 6: Company acquisitions by target service offering, 2023
Figure 7: Company acquisitions by target ownership, 2023
Figure 8: Company acquisitions by target ownership and service type, 2023
Figure 9: Acquisition targets by sophistication of capabilities, 2023
Figure 10: Number of acquisitions, by acquirer’s core business, 2023
Figure 11: Number of acquisitions by acquirer’s ownership, 2023
Figure 12: Number of acquisitions by acquirer’s ownership and target service type
Figure 13: Number of acquisitions by target country, 2023
Figure 14: Most active acquirers, 2023
Figure 15: Dose forms manufactured by acquired manufacturers (all service types), 2023
Figure 16: Top financial advisors to company acquisitions, 2023
Figure 17: Top legal advisors to company acquisitions, 2023
Figure 18: Pharma CMO facility acquisitions, 2023
Figure 19: The contract manufacturing value chain
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acino International AG
- Adragos Pharma Gmbh
- Agno Pharmaceuticals LLC
- Ajinomoto Co Inc
- Anhui Huaren Health Medicine Co Ltd
- Bionorica SE
- Biosynth Ltd
- Cormica Ltd
- Cotecna SA
- Delpharm SAS
- Dermapharm Holding SE
- Eiko LifeSciences Ltd
- Ellimist Singapore Pte Ltd
- EuroAPI SAS
- Eurofins Scientific SE
- Frontage Laboratories Inc
- GBA Group
- Hainan Kangzhe Venture Capital Co. Ltd
- Hwail Pharma Co Ltd
- IPCA Laboratories Ltd
- Juno Pharmaceuticals Inc
- KBI Biopharma Inc
- Life Insurance Corporation of India
- Lifera
- Minafin Group
- NeoPharm Labs Inc
- NEXPOINT LIFE SCIENCES DST
- Nirma Ltd
- Noramco Inc
- NorthX Biologics Matfors AB
- Novo Nordisk AS
- Ofichem BV
- Oxford BioMedica Plc
- Pfizer Inc
- Pharmaids Pharmaceuticals Ltd
- Pharmathen Global BV
- PI Health Sciences Netherlands BV
- Polaris Group Inc
- Porton Pharma Solutions Ltd
- PYFA Australia Pty Ltd
- Rxilient Biohub Pte Ltd
- Saudi Pharmaceutical Industries & Medical Appliances Corp
- SEQENS
- Sharp Packaging Services
- Siegfried Holding AG
- Sigachi Industries Ltd
- SK Pharmteco Inc
- Syngene International Ltd
- Synokem Pharmaceuticals Ltd
- Synthimed Labs Pvt Ltd
- Ubrigene (Beijing) Biology Technology Co Ltd
- Wacker Chemie AG
![Pharmaceutical Contract Manufacturing Market: Trends, Opportunities and Competitive Analysis [2024-2030] - Product Image](http://www.researchandmarkets.com/product_images/12488/12488562_60px_jpg/pharmaceutical_contract_manufacturing_market.jpg)
